Japan IP Court backs Boehringer diabetes drug patents, rejects Nipro challenges
Japan’s Intellectual Property High Court upheld three Boehringer Ingelheim patents covering its diabetes drug linagliptin, rejecting challenges by generics maker Nipro and clarifying that drug patents can remain valid even without...To view the full article, register now.
Already a subscriber? Click here to view full article